BioLineRx Corporation (BLRX) - Gross Profit Margin

Official company branding of BioLineRx Ltd (BLRX)

BioLineRx Ltd. (BLRX) is developing the commercial potential of Aphexda for stem cell mobilization in myeloma, attracting Israeli scientists through a flexible culture and stock options. On GURU.Markets, the trading gross margin demonstrates profitability dynamics, where 55.00 reflects the latest metric value. The high qualification of the management team has ensured the drug's market launch and the establishment of effective global partnerships to scale the therapy.

BLRX (BioLineRx Corporation) Return on Gross Profit history from 07/04/2022 to 11/19/2026

Financial and market metric breakdowns for BioLineRx Ltd (BLRX)

- market price and analyst price targets:
Basic company analysis:BioLineRx (BLRX)
Manufactured products of BioLineRx

BioLineRx Ltd. (BLRX) occupies a high-tech therapy niche where the company's pricing power is driven by the exclusivity of its stem cell mobilization methods. By analyzing changes in gross margin, an investor can see the portion of revenue remaining after direct production costs, reflecting the business's ability to convert premium positioning into actual profit despite restrictive insurance payout limits and inflationary pressure.